Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Sesen Bio Inc

(NASDAQ: SESN)
Add to Portfolio
+0.01 (+0.88%)
as of 10:51 EST

Profile
Ticker Symbol SESN
Exchange NASDAQ
Contact Information
245 FIRST STREET SUITE 1800
CAMBRIDGE, MA USA
P: 617-444-8550
CEO/President Thomas R. Cannell
Earnings at a Glance
Earnings 09/30/19
-0.13
06/30/19
-0.67
03/31/19
-0.08
12/31/18
-0.10
Price Earnings Ratio N/A
EPS Growth 44.55
Most Recent Earnings ($) -0.67
Annual EPS ($) -1.02
Business Summary
Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc. formerly known as Eleven Biotherapeutics is based in Massachusetts United States.
Industry/Sector SIC-2834 Pharmaceutical Preparations
Medical - Biomedical